How a protein called Rap1 affects heart function
Official title: Endothelial Rap1 in the control of heart function
Funded at Versiti Wisconsin, INC. · NIH-11003785 · Data updated 2026-11-12
This study is looking at a protein called Rap1 to see how it helps heart cells talk to each other and affects blood flow, which could lead to better treatments for heart disease and heart failure.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Versiti Wisconsin, INC. NIH-funded |
| Lab location | 1 site (Milwaukee, United States) |
| Project start | January 19, 2022 |
| Project end | December 31, 2025 |
| Funding year | 2025 |
| Award (this year) | $664,924 |
| NIH project number | 5R01HL157893-04 |
| Project ID | NIH-11003785 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals with cardiovascular diseases or those at risk of developing heart failure.
✕Less likely to help
Patients with non-cardiovascular conditions or those without any heart-related issues may not benefit from this research.
What this research studies
This research investigates the role of a protein called Rap1 in heart function, particularly how it influences the communication between heart endothelial cells and heart muscle cells. By studying the effects of Rap1 on nitric oxide production, which is crucial for blood flow and heart muscle health, the research aims to uncover mechanisms that could lead to better heart function. The approach includes examining how the deletion of Rap1 affects heart contractility and the risk of heart failure. Patients may benefit from insights gained about heart disease and potential new treatments.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for treating heart failure and improving heart function.
How similar studies have gone: Previous research has shown promising results in understanding the role of endothelial cells in heart function, suggesting that this approach could yield valuable insights.
Where this research is happening
-
Versiti Wisconsin, INC.
Milwaukee, United States Active
Researchers
- Principal investigator: Chrzanowska, Magdalena — Versiti Wisconsin, INC.
- Study coordinator: Chrzanowska, Magdalena
Related research
Other NIH-funded projects on the same topics.
-
Improving blood safety and availability for transfusions in children and adults
This study is looking to make blood transfusions safer and more accessible for both kids and adults by gathering information from blood donors and recipients across the US and Brazil, so that everyone can benefit from better transfusion practices in the future.
-
Understanding how to safely increase fetal hemoglobin for treating blood disorders
This study is looking at how to safely boost fetal hemoglobin levels in people with blood disorders like beta-thalassemia, by exploring new ways to change certain cells in the body, so that patients can have better treatment options.
-
Understanding how certain proteins regulate blood clotting and cardiovascular diseases
This study is looking at how two proteins that help with blood clotting and heart health work, which could lead to better treatments for blood clotting disorders and heart disease.
-
Targeting a specific gene to treat a type of leukemia
This study is testing a new treatment called AI-10-49 for people with acute myeloid leukemia who have a specific genetic change that makes their condition harder to treat, and it aims to help these patients live longer by killing leukemia cells and working better with other medications.
-
Understanding maternal immune responses affecting newborns with low platelet counts
This study is looking at how a mother's immune system can affect her baby's platelets, which might lead to a serious bleeding condition in newborns, and it aims to find out which pregnancies are at higher risk so that better tests and prevention methods can be developed to help keep babies safe.
-
Understanding the immune response in patients with heparin-induced thrombocytopenia
This study is looking at how the immune system responds to heparin, a blood thinner, to find out more about a serious condition called heparin-induced thrombocytopenia (HIT), and it aims to help doctors better identify harmful antibodies in patients, even if their regular tests come back normal, so they can prevent ser
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.